Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Intangibles (2022 - 2025)

Arcutis Biotherapeutics has reported Intangibles over the past 4 years, most recently at $14.8 million for Q4 2025.

  • Quarterly results put Intangibles at $14.8 million for Q4 2025, up 56.26% from a year ago — trailing twelve months through Dec 2025 was $14.8 million (up 56.26% YoY), and the annual figure for FY2025 was $14.8 million, up 56.26%.
  • Intangibles for Q4 2025 was $14.8 million at Arcutis Biotherapeutics, down from $15.4 million in the prior quarter.
  • Over the last five years, Intangibles for ARQT hit a ceiling of $16.5 million in Q1 2025 and a floor of $6.1 million in Q2 2024.
  • Median Intangibles over the past 4 years was $7.3 million (2022), compared with a mean of $9.7 million.
  • Biggest five-year swings in Intangibles: fell 11.0% in 2024 and later surged 164.0% in 2025.
  • Arcutis Biotherapeutics' Intangibles stood at $7.2 million in 2022, then dropped by 10.43% to $6.4 million in 2023, then soared by 47.24% to $9.5 million in 2024, then surged by 56.26% to $14.8 million in 2025.
  • The last three reported values for Intangibles were $14.8 million (Q4 2025), $15.4 million (Q3 2025), and $15.9 million (Q2 2025) per Business Quant data.